Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma
TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced the initiation of dosing in a clinical trial evaluating the combination of TRC105 and axitinib.09/24/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Opthalmology | Renal Cell Carcinoma | Study | Urology & Nephrology